Evaxion (NASDAQ: EVAX) reported that all patients in the phase 2 trial of its personalized cancer vaccine EVX-01 in advanced melanoma kept their clinical responses at three years, with no tumor progression. In the third year, patients received EVX-01 as stand-alone therapy, after receiving it in combination with KEYTRUDA during the first two years. The new data and immune results will be presented as a poster at ESMO 2026 in Madrid, with a webinar on October 29, 2026. The three-year findings build on two-year results showing a 75% objective response rate, 25% complete responses, and 92% of patients still responding with no relapses. The company says the data strengthen EVX-01's position for potential partnership discussions.
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on finanznachrichten.de ↗
Keywords
Evaxionpharmaceuticalshealthcare
Open a keyword to see other news on the same topic.
Related news
- Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point
- 2 High-Flying Dividend Stocks to Buy and Hold for a Decade
The article argues healthcare is rebounding in 2026, with Merck (MRK) shares up 39% and AbbVie (ABBV) up 24% year to date, versus about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating estimates, with Keytruda sales of $8.4 billion, though Keytruda may lose patent exclusivity by 2028. AbbVie's second-quarter revenue grew 10.2% to nearly $17 billion and adjusted EPS rose 22.9% to $3.65, driven by Skyrizi and Rinvoq sales growing about 24%. AbbVie is on a streak of 54 consecutive annual dividend increases, including its time as part of Abbott Laboratories, qualifying it as a Dividend King. The author concludes both are attractive long-term holdings based on financial results, pipelines, and dividends.
- Where Will CRISPR Therapeutics Stock Be in 2030?
Shares of CRISPR Therapeutics have fallen about 47% since mid-October 2021, while the S&P 500 has gained almost 73% as of writing, despite clinical and regulatory progress over the past five years. Casgevy, developed with Vertex Pharmaceuticals, was approved in 2023 and early 2024 for transfusion-dependent beta-thalassemia and sickle cell disease, making it the company's first commercial product and the first approved CRISPR-based gene-editing therapy. Other candidates include CTX310, aimed at lowering LDL cholesterol and triglycerides, where Phase 1 data showed significant decreases in both; zugo-cel for autoimmune diseases and blood cancers; and CTX611, an anticoagulant that could be given twice a year. Casgevy's label now covers patients as young as two, adding about 5,500 U.S. patients at $2.2 million per treatment course. The article warns of possible clinical failures and the costly, one-time nature of many gene-editing therapies, which makes profitability uncertain.
- Medicare open enrollment : Why premiums could increase for some enrollees
Medicare open enrollment runs from Oct. 15 to Dec. 7, with changes taking effect Jan. 1. The annual out-of-pocket cap for Part D drugs rises to $2,400 from $2,100 in 2026, the standard deductible increases from $615 to $700, and the Trump administration is ending a temporary Part D premium subsidy. According to KFF, enrollees in United AARP-branded Part D plans who don't change plans will see monthly premiums rise by $50 or more in all 50 states, and by more than $75 in 37 states. Fifteen drugs, including Ozempic, Rybelsus and Wegovy, will get Medicare-negotiated prices, and the Centers for Medicare and Medicaid expects the change to reduce prescription drug coverage costs for enrollees by $685 million in 2027. KFF notes many enrollees don't compare plans during open enrollment, even though cheaper options exist.
- Amazon.com (AMZN) Received An FDA Warning Over Unapproved STI Drug Listings
On October 15, 2026, Amazon.com (AMZN) received an FDA warning letter over unapproved drug products for sexually transmitted infections. The FDA cited several marketplace listings marketed as treatments or cures without required drug approvals and warned that continued sales could lead to product seizures or injunctions if the issues are not corrected. The article views this as a test of Amazon's marketplace controls and platform governance rather than its AI growth story, and says the company's disclosures and future FDA updates will be the clearest measure of the impact.
- Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
BioNTech (NASDAQ: BNTX) held 16.6 billion euros in cash, cash equivalents and securities at the end of the second quarter and announced a share repurchase program of up to $1 billion. Its only commercialized product is the COVID-19 vaccine Comirnaty, developed with Pfizer, while the company aims to become a multiproduct oncology business by 2030. It reports 14 ongoing pivotal trials, including seven evaluating pumitamig, a candidate developed with Bristol Myers Squibb. Of the 20 analysts covering the stock, 13 rate it a strong buy and the rest a hold, with target prices implying 5% to 64% upside (average 39%). The stock trades at a price-to-sales ratio of 7, and the article flags trial failures, approval delays and declining COVID-19 vaccine revenue as key risks.
Related markets
Latest news
- Chips Are Selling Off and Apple Just Hit a New High. What Splits the AI Trade
Chip stocks sold off last week, with the iShares Semiconductor ETF (NASDAQ:SOXX) down 13.31%, while Apple (NASDAQ:AAPL) rose 2.11% and sits about 1.5% below its 52-week high. The article argues Apple benefits from AI by selling it across more than 2.5B active devices, rather than through heavy infrastructure spending like hyperscalers, and notes revenue grew 16.4% year over year last quarter. The stock trades at $342.96 against a 24/7 Wall St. 12-month target of $397.78 (15.99% upside), with a bull case of $451.56 driven by Siri AI and iCloud Plus upgrades. Risks include memory costs, which Cook called “a 100-year flood,” and gross margin guidance of 47% to 48%; the consensus target of $329.38 sits below the current price. The piece also compares Apple’s P/E with NVIDIA and Microsoft, concluding Apple has less exposure to AI infrastructure spending.
- September data shows housing market in a deep freeze
Rising mortgage rates took a harsh toll on the housing market in September. Pending home sales, which measure signed contracts on existing homes, fell 7.3% from August and 11.3% year over year, according to the National Association of Realtors. The average 30-year fixed mortgage rate climbed from about 6.8% to 7.6% during the month, and sales fell most sharply in the South (-8.2%) and West (-9.2%). Housing starts dropped 4.56% to 859,000 annualized, the lowest since September 2025, and building permits fell 4%. Homebuilder sentiment in October hit its lowest level in 14 years, and economists expect construction to stay weak into 2027.
- Revealed: the foreign 'big spender' that has poured over USD 100 billion into Vietnam
Foreign direct investment (FDI) registered in Vietnam topped USD 50 billion in the first nine months of 2026, up 76.4% year on year, while disbursed FDI reached over USD 21.07 billion. Singapore led with USD 12.85 billion in registered capital, up nearly 86% and over a quarter of the national total, ahead of South Korea at over USD 3.1 billion. Singapore's new projects totaled USD 9.26 billion, with USD 2.32 billion in capital increases at existing projects and over USD 1.26 billion in capital contributions and share purchases in domestic firms. Cumulatively, Singapore has passed USD 101.5 billion, becoming the second partner to exceed USD 100 billion and narrowing the gap with South Korea to about USD 2.7 billion. The Ministry of Finance attributes the inflows to the Strategic Partnership and cooperation in green and digital economy.
- Savings interest rates on October 20 at Agribank, Vietcombank, VietinBank and BIDV: Large gaps at 12-24 month terms
After Agribank and Vietcombank cut deposit rates, the rates at the four state-owned banks diverged more clearly. For 1-3 month terms, Agribank is highest at 2.6%-2.9% per year, while Vietcombank, VietinBank and BIDV offer 2.1%-2.4%. For 6-9 months, Vietcombank's 3% per year is below the 3.5% offered by the other three. From 12 months up, BIDV and VietinBank stay higher, at 5.9% for 12 months and 6% for 24 and 36 months, while Vietcombank offers 4.8% for 36 months. These are counter rates for individual customers and may change by term, deposit amount, channel and each bank's policy.
- Anthropic Will Be The Last AI IPO Of 2026, As Industry Collapses
Business Insider founder Henry Blodget noted Anthropic’s month-over-month revenue growth flattened last month, while the article says AI funding is tightening: CoreWeave (NASDAQ: CRWV) is paying up to 13% on new debt, SoftBank has debt problems, and as many as 1,000 communities are trying to block AI data centers. Borrowing for data centers could reach $1 trillion a year through 2030, and shares in AI data center company Elice fell 33% on its IPO launch, the worst opening day for a sizable Korean IPO according to Bloomberg data. The article says Anthropic could be valued at around $2 trillion on IPO day, but under GAAP it is not profitable despite management’s claims, and a trust controlling the board has incomplete disclosures. It concludes Anthropic may list, possibly below $2 trillion, while no other AI firm is likely to IPO this year.
- Amazon to hire over 300,000 holiday workers, up 20% from last year
Amazon plans to hire more than 300,000 workers across its U.S. core operations network for the holiday season, a 20% increase over last year, while overall retail hiring is expected to soften to its lowest level since 2008. Seasonal starting wages average $20 per hour, and full-time core operations staff average nearly $24 per hour. From January 1, 2027, Amazon will extend healthcare benefits to seasonal employees working at least 30 hours per week, with plans starting at $5 per week. The company has committed more than $1.5 billion to wage increases, bringing average full-time compensation including benefits to over $32 per hour. The article frames these moves as a way to shield the supply chain from labor bottlenecks during peak demand.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.